Safety and effectiveness of pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer

Objective:To investigate the safety and effectiveness of the pemetrexed in the treatment of the initial or recurrent advanced non-small cell lung cancer(NSCLC).Methods:The 18 cases of the first-line treatment and 23 cases of the secondary-line treatment in 41 cases with advanced NSCLC identified by pathology or cytology were treated with 500 mg/m² of pemetrexed at the first day combined with 25 mg/m² of cisplatin at 2, 3 and 4 days or 5 AUC of carboplatin at the first day by intravenous drip, 3 weeks for a course.The safety and effectiveness of treatment were evaluated.Results:Partial response in 7 cases, stabilization in 4 cases, progress in 7 cases and no complete response cases in 18 cases with the first-line treatment were found, the effective rate and disease control rate were 38.89% and 61.11%, respectively, and the median progression-free survival time of which was 6.8 months.Partial response in 2 cases, stabilization in 9 cases, progress in 12 cases and no complete response cases in 23 cases with the second-line treatment were found, the effective rate and disease control rate were 8.70% and 47.83%, respectively, and the median progression-free survival time of which was 2.6 months.The major adverse reactions in two groups included fatigue, white blood cells decreasing, anemia and gastrointestinal tract reaction.Conclusions:The effects of pemetrexed combined with platinum in the first-line and second-line treatment of advanced NSCLC are good, high safety and good tolerance.